Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review

Zhou, Xu; Liu, Meilu; Ren, Qing; Zhu, Weifeng; Wang, Yang; Chen, Haochen; Chen, Jianrong

doi:10.1186/s12906-019-2779-y

BMC Complementary Medicine and Therapies

Table 1 Characteristics of included randomized controlled trials

From: Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review

Study	No. of patients		Stage of gastric cancer	MTE (type and dose)	Chemotherapy regimen for both groups	Co-intervention for side effects	Length of follow up (week)	Outcome
Study	MTE group	Control group	Stage of gastric cancer	MTE (type and dose)	Chemotherapy regimen for both groups	Co-intervention for side effects	Length of follow up (week)	Outcome
Deng 2016 [20]	15	15	Advanced	MTE injection, 80 ml/d for 7 d, 2 sessions	TP	5-HT3 antagonists	6	a,b,c
Gao 2015 [21]	92	91	Advanced	MTE injection, 40 ml/d for 14 d, 2 sessions	XELOX	Tropisetron and CSF	16	a,c,d,e,g
Gao 2017 [22]	33	33	IV	MTE injection, 80 ml/d for 14 d, 4 sessions	TP	NR	12	a,b,c,d,e,g
Huang 2013 [23]	36	36	Early stage with radical gastrectomy	MTE tablet, 2.4 g/time, 3 times/d for 30 d, 2 sessions	FOIFOX/XELOX/EOF	NR	26	c,d,
Huo 2009 [24]	31	31	Advanced	MTE tablet, 2.4 g/time, 3 times/d for 30 d, 2 sessions	FOIFOX	Granisetron	8	a
Keyoumu 2012 [25]	33	35	III and IV	MTE injection, 60 ml/d for 7 d, 2 sessions	FOLFOX	Ondansetron	14.2	a,b,c,d,e,g,h
Li 2016 [26]	60	60	IV	MTE injection, 80 ml/d for 14 d, 4 sessions	CPT-11	NR	8	a,c,e,g,h,i
Lin 2015 [27]	28	28	Advanced	MTE injection, 60 ml/d for 14 d, 2 sessions	XELOX	Tropisetron, metoclopramide, vitamin B6, and CSF	6	a,b,c,d,e,f,g,i
Liu 2012 [28]	28	28	IV	MTE injection, 80 ml/d for 7 d, 4 sessions	FOLFOX	5-HT3 antagonists	8	a,c,d,e,f,g
Liu 2017 [29]	48	48	III and IV	MTE injection, 60 ml/d for 14 d, 2 sessions	SOX	Palonosetron and metoclopramide	12	a,b,c,d,g,h,i
Ma 2015 [30]	23	23	Advanced	MTE injection, 60 ml/d for 7 d, 2 sessions	SOX	NR	6	b,c
Shi 2017 [31]	53	53	Early stage with radical gastrectomy	MTE tablet, 2.4 g/time, 3 times/d for 30 d, 2 sessions	EOF/OLF	NR	26	c,d,
Xiong 2015 [32]	32	32	IV	MTE injection, 80 ml/d for 21 d, 4 sessions	chemotherapy	Vitamin	12	a,g,i,j
Zhang HY 2015 [33]	46	46	III and IV	MTE capsule, 2.0 g/time, 2 times/d for 30 d, 2 sessions	PF	NR	8	a,b,c,d
Zhang H 2015 [34]	25	23	Advanced	MTE injection, 40 ml/d for 14 d, 2 sessions	XELOX	CSF	6	a,b,c,d,e,f,g,h
Zheng 2017 [35]	42	42	III and IV	MTE injection, 60 ml/d for 21 d, 2 sessions	chemotherapy	NR	18	a,c,d,e,g,h,i,j
Zhu 2017 [36]	40	40	Advanced	MTE injection, 60 ml/d for 14 d, 4 sessions	FOLFOX	Tropisetron	8	a,c,d,e,g,h

Abbreviations: T trial group; C control group; MTE Marsdenia tenacissima extract; NR not reported; FOLFOX folinic acid + fluorouracil + oxaliplatin; XELOX capecitabine + oxaliplatin; TP docetaxel + cisplatin; SOX S-1 + oxaliplatin; EOF epirubicin + oxaliplatin + fluorouracil; OLF oxaliplatin + leucovorin + flurouracil; CPT-11 irinotecan; PF cabazitaxel + Platinum + fluorouracil; CSF colony stimulating factor
Outcomes: a = response to treatment; b = performance status; c = myelosuppression; d = gastrointestinal reactions; e = hepatic injury; f = kidney injury; g = neurotoxicity; h = oral mucosal lesions; i = progression-free survival; j = overall survival

Back to article page

ISSN: 2662-7671

Contact us

Submission enquiries: bmccomplementarymedicineandtherapies@biomedcentral.com
General enquiries: ORSupport@springernature.com